Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects

CONTEXT: The SELECT trial led to the approval of lenvatinib for the treatment of advanced radioiodine-refractory differentiated thyroid carcinomas (DTCs) but also revealed an important adverse event (AE) profile which may limit its use in clinical practice. OBJECTIVE: We aim to describe the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamidi, Sarah, Boucher, Andrée, Lemieux, Bernard, Rondeau, Geneviève, Lebœuf, Rebecca, Ste-Marie, Louis-Georges, Le, Xuan Kim, Mircescu, Hortensia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032633/
https://www.ncbi.nlm.nih.gov/pubmed/35475024
http://dx.doi.org/10.1210/jendso/bvac048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032633/
https://www.ncbi.nlm.nih.gov/pubmed/35475024
http://dx.doi.org/10.1210/jendso/bvac048

Ejemplares similares